We are live on ! Find out more
CRSP icon

CRISPR Therapeutics
CRSP

446 hedge funds and large institutions have $3.25B invested in CRISPR Therapeutics in 2021 Q4 according to their latest regulatory filings, with 76 funds opening new positions, 161 increasing their positions, 128 reducing their positions, and 96 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 2 → 4 (+2)

26% more repeat investments, than reductions

Existing positions increased: 161 | Existing positions reduced: 128

3.02% more ownership

Funds ownership: 52.96% → 55.98% (+3%)

8% more call options, than puts

Call options by funds: $219M | Put options by funds: $202M

6% less funds holding

Funds holding: 473 → 446 (-27)

21% less first-time investments, than exits

New positions opened: 76 | Existing positions closed: 96

28% less capital invested

Capital invested by funds: $4.52B → $3.25B (-$1.27B)

Holders
446
Holders Change
-27
Holders Change %
-5.71%
% of All Funds
6.86%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.06%
New
76
Increased
161
Reduced
128
Closed
96
Calls
$219M
Puts
$202M
Net Calls
+$17M
Net Calls Change
+$115M

Top Buyers

Rank Fund Capital Flow
1
AIM
ARK Investment Management
Florida
+$131M
2
EC
EcoR1 Capital
California
+$94.1M
3
NAMA
Nikko Asset Management Americas
New York
+$90M
4
Renaissance Technologies
Renaissance Technologies
New York
+$50.6M
5
AC
Armistice Capital
New York
+$44.7M

Top Sellers

Rank Fund Capital Flow
1
Macquarie Group
Macquarie Group
Australia
-$85.9M
2
O
OrbiMed
New York
-$68.6M
3
Capital International Investors
Capital International Investors
California
-$51.2M
4
Bank of America
Bank of America
North Carolina
-$32.7M
5
Marshall Wace
Marshall Wace
United Kingdom
-$28.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
PFM
451
Premier Fund Managers
United Kingdom
– -$6.35M -57,600 Closed
Arrowstreet Capital
452
Arrowstreet Capital
Massachusetts
– -$5.27M -47,100 Closed
SC
453
Shellback Capital
Massachusetts
– -$4.48M -40,000 Closed
CM
454
Capula Management
Cayman Islands
– -$3.85M -34,442 Closed
SOMRS
455
State of Michigan Retirement System
Michigan
– -$3.63M -32,386 Closed
IC
456
Ikarian Capital
Texas
– -$3.13M -27,968 Closed
TCM
457
Traynor Capital Management
Pennsylvania
– -$2.93M -26,195 Closed
Man Group
458
Man Group
United Kingdom
– -$2.77M -24,759 Closed
ACM
459
Advisors Capital Management
New Jersey
– -$2.77M -24,748 Closed
State of Wisconsin Investment Board
460
State of Wisconsin Investment Board
Wisconsin
– -$2.57M -22,961 Closed
Schroder Investment Management Group
461
Schroder Investment Management Group
United Kingdom
– -$2.19M -19,570 Closed
CPC
462
Cookson Peirce & Co
Pennsylvania
– -$1.69M -15,053 Closed
PP
463
Peconic Partners
New York
– -$1.68M -15,000 Closed
1CM
464
1492 Capital Management
Wisconsin
– -$1.04M -9,256 Closed
SWM
465
SeaCrest Wealth Management
New York
– -$1.03M -9,218 Closed
PP
466
PDT Partners
New York
– -$885K -7,906 Closed
BSAM
467
Blue Square Asset Management
New York
– -$830K -7,412 Closed
XT
468
XTX Topco
Cayman Islands
– -$811K -7,248 Closed
WAM
469
Werlinich Asset Management
Connecticut
– -$726K -6,485 Closed
CCM
470
Cinctive Capital Management
New York
– -$672K -6,000 Closed
LP
471
LMR Partners
United Kingdom
– -$635K -5,673 Closed
BWAM
472
Boyd Watterson Asset Management
Ohio
– -$632K -5,648 Closed
EWA
473
Exencial Wealth Advisors
Oklahoma
– -$565K -5,049 Closed
CAM
474
Concorde Asset Management
Michigan
– -$535K -4,782 Closed
NAG
475
Northstar Advisory Group
New Jersey
– -$503K -4,495 Closed
17 18
19
20 21

CRSP Hedge Fund Activity: Q4 2021 in Review

446 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q4 2021, worth a combined $3.25B — down 28% from $4.52B a quarter earlier.

Sellers outnumbered buyers: 96 funds closed out of CRSP and 76 opened new positions — a net loss of 20 holders — while 128 trimmed existing stakes and 161 added.

The largest buyer was ARK Investment Management, adding an estimated $131M. The largest seller was Macquarie Group, cutting an estimated $85.9M.

  • 446 institutional investors held CRISPR Therapeutics (CRSP) as of Q4 2021, down from 473 in Q3 2021.
  • Funds reported $3.25B of CRISPR Therapeutics stock for Q4 2021, down 28% quarter-over-quarter.
  • 76 funds opened new CRISPR Therapeutics positions in Q4 2021 and 96 closed out, a net change of -20 holders.
  • The largest CRISPR Therapeutics buyer in Q4 2021 was ARK Investment Management, an estimated $131M added.
  • The largest CRISPR Therapeutics seller in Q4 2021 was Macquarie Group, an estimated $85.9M sold.

Based on aggregated 13F filings for Q4 2021.